An much more complicated drawback would come up if one good vaccine is obtainable however different, presumably higher, vaccines are imminent. Does everybody get the “ok” vaccine, disrupting the flexibility to conduct medical trials to see if the opposite vaccines are higher? How a lot persistence do People have, actually?
People would in all probability resent having to attend. But when they find yourself selecting a lesser high quality vaccine, over the long term they could be unhappier but. It isn’t clear the U.S. public well being paperwork is as much as the duty of approving one vaccine and restructuring the opposite trials (presumably by paying contributors extra to remain in, or by shifting to different international locations for information) to allow them to proceed.
The problems do not get any simpler in case you contemplate therapeutics corresponding to monoclonal antibodies. Doubtless they’ve efficacy, however current proof exhibits they can’t be given too late in the midst of remedy. In different phrases, you can’t wait to see which sufferers are faring badly after which deal with them. On the similar time, monoclonal antibodies are troublesome to fabricate and distribute, and they’re anticipated to be costly. So how precisely will they be allotted?
One smart strategy is to present them preemptively to these engaged on the entrance strains, corresponding to nurses and medical doctors. Nonetheless, many extra People will need them. It will likely be troublesome for any administration to say they can not have the remedy as a result of they’re too far superior of their coronavirus an infection. In case you really feel dangerous, it’s possible you’ll be determined to strive them (they usually in all probability will not damage you); and even in case you really feel OK, it’s possible you’ll suppose that it’s precisely the fitting time to take them (quickly sufficient to make a distinction, and in addition to, aren’t People well-known for demanding overtreatment?).